| - Pojem - | - Vysvětlení - |
| Vepesid | Etoposid |
| OS (Overall Survival) | Defined as the time from randomization (or treatment initiation in single-arm studies) to death from any cause. |
| DFS (Disease-Free Survival) | Time from randomization to disease recurrence or death, used primarily in adjuvant (post-surgical/radiation) settings. |
| PFS (Progression-Free Survival) | Time from randomization to documented tumor progression or death, often used in advanced/metastatic settings. |
| ORR (Objective Response Rate) | The proportion of patients achieving tumor shrinkage (CR or PR) per standardized criteria (e.g., RECIST 1.1 for solid tumors). |
| CR (Complete Response) | Disappearance of all target lesions and normalization of tumor markers for a minimum duration (usually ≥4 weeks). |
| PR (Partial Response) | ≥30% reduction in the sum of diameters of target lesions, maintained for at least 4 weeks. |
| SD (Stable Disease) | Insufficient shrinkage for PR and insufficient increase for PD. |
| PD (Progressive Disease) | ≥20% increase in the sum of target lesion diameters or appearance of new lesions. |
| DCR (Disease Control Rate) | Proportion of patients with CR, PR, or SD maintained beyond a minimum duration. |
| FOLFOX | folinová kyselina a 5-fluorouracyl a oxaliplatina |
| FOLFIRI | folinová kyselina a 5-fluorouracyl a irinotecan |
| FOLFIRINOX | folinová kyselina a irinotecan a oxaliplatina |
| XELOX (CELOX, CAPEOX) | kapecitabin a oxaliplatina |
| de Gramont | folinová kyselina a 5-fluorouracyl |
| CBDCA | carboplatina: nefrotoxicita |
| OXA | oxaliplatin neurotoxicita sodíkové kanály |
| cDDP | cisplatin ototoxicita |
| LiFraumeni | |
| Ki67 | |
| SSME | |
| SNBL | |
| AE SSE-FIM | |
| NACHT 4AC | |
| infliximab | |
| ovosan | |
| Lynparza | |
| Lymfoscintigrafie | |
| capecitabin | |
| Keytruda | |
| Fulvestrant | |
| Tamoxifen | |
| Enhertu | |
| syndrom přeživších (únava), následky chemoterapie | |
| opakovaně vypadávání obočí i po ukončení | |
| OS = ovariální suprese | |
| expandér prsu | |
| osenvelt | |
| osteonekróza maxily po denosumabu | |
| everolimus | |
| anti-her -> echo (redukce ejekční frakce) | |
| enfortumab vendotin | |
| keytruda | |
| Essentiale 1-1-0 | |
| cabometix -> agousie, průjem, zastřený hlas | |
| Xtendi | |
| zoladex | |
| RRSO | risk-reducing salphingo-oophorectomy |
| RRME | risk-reducing mastectomy |
| IA | inihibitor aromatázy |
| FES PET/CT | fluoroestrogen PET/CT |
| CxDy | cyklus den |
| paclitaxel | prevence neuropatie, rukavice, podkolenky |
| zoladex | depot |
| Phesgo | |
| Xgeva | |
| TM | tumor markery |
| scalpcooling | |
| Osenvelt | |
| Everolimus | |
| Sandostatin somatuline | |
| acofil | |
| etoposid | |
| Lumykras | |
| Trozel | |
| Somatulin | |
| antiresorpční terapie | |
| Durvalumab | |
| Pembrolizumab | |
| Levantinib | |
| Paclitaxel weekly | intenzivnější (standard je á 3 týdny), mezikrok biweekly |
| FOLFIRI | |
| deGramond | |
| erbitux | |
| UGT1A1 irinotecan | |
| OS | ovariální suprese |
| prsní expandér | |
| ADT | léčba androgen deprivační terapie |
| ruborózní efekt | |
| SSA | somatostatinová analoga |
exemestan FISH Xyloda hormonální terapie ztuhlost kloubů zajímavost je hepatotoxicita u hepatopatie CDK4i leukopenie Zytiga + Prednison alverateron Verzenios Kadeyla platinové deriváty mají podobný efekt jako PARP inhibitory Ibrance Imfinzi Hormonální profil FLOT Trodevy BAP1
Alozex Enhertu syndrom přeživších Xtendy (únava, slabost) Zoledex následky chmt i po 6m vypadávání obočí somakit
pánevní kongesce
| pembrolizumab | Keytruda |
| atezolizumab | |
| nivolumab | Obdivo |
| durvalumab |
vinorelbin spinocellulární alembrique
Spirometrie:
| DLCO | |
| FEV1 | |
| TLC | total lung capacity |
| RV | |
| VC |
| ProGRP | SCLC |
| CEA | adenokarcinom plic |
| CYFRA | adenokarcinom plic |
| NSE | adenokarcinom plic |
| CA-19-9 | |
| CA-125 | vaječník |
| chromogranin | karcinoid (nesmí se užívat PPI) |
| PSA | prostata |
| C50 | prso |
| C20 | konečník |
| C34 | plíce |
| C61 | prostata |
komplikace implantátů 15–20 %
Wilkieho syndrom rekonstrukční výkon, muskulární blok
parciální výkon -> radioterapie
Lynparza
Kadeyla Trodelvy
antracykliny + taxany
NGS 1x ročně
Kastračně rezistentní
Zytiga + Prednison (substituce) Zoladex abirateron
paclitaxel weekly + cbdca
ras bevacizumab
Absolute Neutrophil Count (ANC):
| >2 | G0 |
| 1.5-2 | G1 |
| 1.0-1.5 | G2 |
| 0.5-1.0 | G3 |
| <0.5 | G4 |
MUDr. Bouzek: infuze jmelí